New York, New York (PRWEB) September 24, 2014
Americord announced today that it has provided funding to support a clinical trial investigating the efficacy of autologous umbilical cord blood for the treatment of pediatric patients with cerebral palsy.
This trial is being conducted under the direction of an internationally renowned expert in umbilical cord blood transplantation. The purpose is to determine whether infusions of a child's own cord blood can lessen the symptoms of cerebral palsy. The goal of the trial explores the potential of discovering how cord blood could be used for other purposes, including reducing inflammation in the brain and producing new hormones to repair damaged brain cells.
“This research for children with cerebral palsy is truly exciting,” said Americord CEO Martin Smithmyer. “We will be following this trial with great interest and we are thrilled to provide funding to help support it.” Americord’s funding has been made through its corporate giving program, which was established to support research focused on the therapeutic uses of stem cells from umbilical cord blood, cord tissue, and placenta tissue.
About Americord Registry
Americord Registry is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. Visit http://americordblood.com/ for more information.